These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 27392463

  • 21. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
    Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sárdy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, Anders HJ.
    Am J Pathol; 2010 Jun; 176(6):2840-7. PubMed ID: 20413687
    [Abstract] [Full Text] [Related]

  • 22. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice.
    Zoja C, Liu XH, Donadelli R, Abbate M, Testa D, Corna D, Taraboletti G, Vecchi A, Dong QG, Rollins BJ, Bertani T, Remuzzi G.
    J Am Soc Nephrol; 1997 May; 8(5):720-9. PubMed ID: 9176841
    [Abstract] [Full Text] [Related]

  • 23. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-κB activation.
    Zhao J, Zhang H, Huang Y, Wang H, Wang S, Zhao C, Liang Y, Yang N.
    Int Immunopharmacol; 2013 Sep; 17(1):116-22. PubMed ID: 23770281
    [Abstract] [Full Text] [Related]

  • 24. Association of monocyte chemoattractant protein 1 (MCP-1) gene polymorphism with lupus nephritis in Egyptian patients.
    Mohammad LA, Atef DM, Abul-Saoud AM.
    Hum Immunol; 2015 Oct; 76(10):724-8. PubMed ID: 26429331
    [Abstract] [Full Text] [Related]

  • 25. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice.
    Ninichuk V, Clauss S, Kulkarni O, Schmid H, Segerer S, Radomska E, Eulberg D, Buchner K, Selve N, Klussmann S, Anders HJ.
    Am J Pathol; 2008 Mar; 172(3):628-37. PubMed ID: 18258851
    [Abstract] [Full Text] [Related]

  • 26. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
    Patole PS, Gröne HJ, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Schlöndorff D, Anders HJ.
    J Am Soc Nephrol; 2005 May; 16(5):1326-38. PubMed ID: 15772251
    [Abstract] [Full Text] [Related]

  • 27. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice.
    Nozaki Y, Yamagata T, Yoo BS, Sugiyama M, Ikoma S, Kinoshita K, Funauchi M, Kanamaru A.
    Clin Exp Immunol; 2005 Jan; 139(1):74-83. PubMed ID: 15606616
    [Abstract] [Full Text] [Related]

  • 28. CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice.
    Wu X, Guo J, Ding R, Lv B, Bi L.
    Acta Histochem; 2015 Oct; 117(8):732-7. PubMed ID: 26456520
    [Abstract] [Full Text] [Related]

  • 29. Bradykinin 1 receptor blockade subdues systemic autoimmunity, renal inflammation, and blood pressure in murine lupus nephritis.
    Qin L, Du Y, Ding H, Haque A, Hicks J, Pedroza C, Mohan C.
    Arthritis Res Ther; 2019 Jan 08; 21(1):12. PubMed ID: 30621761
    [Abstract] [Full Text] [Related]

  • 30. The Friend leukaemia virus integration 1 (Fli-1) transcription factor affects lupus nephritis development by regulating inflammatory cell infiltration into the kidney.
    Sato S, Zhang XK.
    Clin Exp Immunol; 2014 Jul 08; 177(1):102-9. PubMed ID: 24580413
    [Abstract] [Full Text] [Related]

  • 31. Treatment with lysophosphatidic acid improves glomerulonephritis through the suppression of macrophage activation in a murine model of systemic lupus erythematosus.
    Nagata W, Takayama E, Nakagawa K, Koizumi A, Ohsawa Y, Goto H, Yamashiro A, Ishinoda Y, Tanoue K, Kumagai H, Oshima N, Ishizuka T.
    Clin Exp Rheumatol; 2024 Mar 08; 42(3):658-665. PubMed ID: 38436267
    [Abstract] [Full Text] [Related]

  • 32. Ac-SDKP ameliorates the progression of lupus nephritis in MRL/lpr mice.
    Tan H, Zhao J, Wang S, Zhang L, Wang H, Huang B, Liang Y, Yu X, Yang N.
    Int Immunopharmacol; 2012 Dec 08; 14(4):401-9. PubMed ID: 22922317
    [Abstract] [Full Text] [Related]

  • 33. [Expression of monocyte chemoattractant protein-1 and lupus nephritis].
    Liu ZJ, Lin JY.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Aug 08; 27(4):491-5. PubMed ID: 16178446
    [Abstract] [Full Text] [Related]

  • 34. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis.
    Lema GP, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, Schlöndorff D.
    J Am Soc Nephrol; 2001 Jul 08; 12(7):1369-1382. PubMed ID: 11423566
    [Abstract] [Full Text] [Related]

  • 35. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice.
    Gu Z, Akiyama K, Ma X, Zhang H, Feng X, Yao G, Hou Y, Lu L, Gilkeson GS, Silver RM, Zeng X, Shi S, Sun L.
    Lupus; 2010 Nov 08; 19(13):1502-14. PubMed ID: 20647254
    [Abstract] [Full Text] [Related]

  • 36. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2002 Aug 08; 46(8):2121-31. PubMed ID: 12209517
    [Abstract] [Full Text] [Related]

  • 37. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis.
    Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, Szeto CC.
    Nephrol Dial Transplant; 2006 Jun 08; 21(6):1534-40. PubMed ID: 16449281
    [Abstract] [Full Text] [Related]

  • 38. Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus.
    Wolf VL, Taylor EB, Ryan MJ.
    Physiol Rep; 2019 May 08; 7(10):e14059. PubMed ID: 31124322
    [Abstract] [Full Text] [Related]

  • 39. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
    Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K, Velden J, Hopfer H, Fehr S, Krieger T, Meyer-Schwesinger C, Meyer TN, Helmchen U, Mittrücker HW, Stahl RA, Panzer U.
    J Immunol; 2009 Oct 01; 183(7):4693-704. PubMed ID: 19734217
    [Abstract] [Full Text] [Related]

  • 40. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus.
    Chong BF, Mohan C.
    Expert Opin Ther Targets; 2009 Oct 01; 13(10):1147-53. PubMed ID: 19670960
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.